Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Glioblastoma 9Gliosarcoma 6Brain Neoplasms 6Rectal Neoplasms 2Oligodendroglioma 2Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Astrocytoma 2Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1

Interventions

Gemcitabine 5Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Leucovorin 3Irinotecan 3Erlotinib Hydrochloride 3Bevacizumab 3ulixertinib 2tovorafenib 2pembrolizumab 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × cediranib × CNS × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡